Biotech Values

[DewDiligence]

TCON oddity (from 2Q17 CC)—the TRAXAR trial, an event-driven phase-2 testing Inlyta ± TRC105 in refractory RCC (https://www.clinicaltrials.gov/ct2/show/NCT01806064 ) may be stopped by TCON at ~80 events rather than the intended 110 events if management sees that the event rate is “plateauing,” despite the obvious loss of statistical power from doing so.

I don’t get it. (One of the CC analysts asked why this might be done, but the answer was unhelpful.)